Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 9/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 7/20 | 0.40 |
| ▸ | WNT3 | P56703 | 1/20 | 0.39 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | CCR8 | P51685 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2188583 | 0.87 | CYP3A4 (0.47) | WNT3SFRP1TGFBR1STS | |
| SCHEMBL7931112 | 0.78 | USP30 (0.51) | SFRP1GPR119TGFBR1STS | |
| SCHEMBL29081264 | 0.75 | CHRM2 (0.39) | NR1H2KDM1A | |
| SCHEMBL26848604 | 0.75 | CHRM2 (0.39) | NR1H2KDM1A | |
| SCHEMBL26848640 | 0.75 | CHRM2 (0.39) | NR1H2KDM1A | |
| SCHEMBL1722375 | 0.75 | CACNA1B (0.49) | — | |
| SCHEMBL31251393 | 0.71 | POLB (0.44) | GPR119MEN1KMT2A | |
| SCHEMBL16228718 | 0.71 | POLB (0.44) | GPR119MEN1KMT2A | |
| SCHEMBL16228721 | 0.71 | POLB (0.44) | GPR119MEN1KMT2A | |
| SCHEMBL24364142 | 0.70 | CHRM2 (0.41) | NR1H2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172236-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CHAKRAVARTY PRASUN K | 2011-07-14 | — | — | US | disclosed |
| WO-2010036589-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK SHARP & DOHME CORP. (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172236-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | TRPV1, TRPA1, CACNA1D | NR1H2 744/4885NR1H3 1079/4885WNT3 4519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.